Pharma Marketing Network

JUNE 16, 2025

For example, identifying HCPs who treat a high volume of patients with a specific condition—such as type 2 diabetes—enables the delivery of product-specific materials like Jardiance or Ozempic based on relevance. Educational webinars, white papers, and digital reprints are performing well, especially when endorsed by credible experts.

HIPAA

Pharma Marketing Network

JULY 7, 2025

For example, a diabetes drug brand may run display ads while simultaneously sending educational emails. For example, tracking a user’s journey from a search ad to a white paper download offers valuable insight into funnel behavior. These are ideal for promoting CME courses, white papers, and clinical trial updates.

Labelling

Pharmacy Times

AUGUST 6, 2025

Pharmacists as partners in pediatric immunizations: a white paper from the Pediatric Pharmacy Association. Community-based outreach key to national vaccination program. August 2, 2024. Accessed July 16, 2025. Girotto JE, Klein KC, Cober MP, et al. J Pediatr PharmacolTher. 2024;29(6):660-666. doi:10.5863/1551-6776-29.6.660 6.

Vaccines

pharmaphorum

JUNE 24, 2025

Skip to main content Tuesday 24 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

Pharmaceutical Technology

JUNE 6, 2025

Find out more RTU cartridges are essential for storing glucagon-like peptide-1 drugs, biologics, insulin and hormone therapies used for treating diabetes, obesity and other immunological conditions. It will further extend the site’s manufacturing capabilities for high-value solutions.

Health and Personal Care Stores

pharmaphorum

JULY 14, 2025

Skip to main content Monday 14 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

Pharmaceutical Technology

JUNE 18, 2025

The full UK test will also look at a person’s susceptibility to developing type 2 diabetes, prostate cancer and breast cancer. The test was also evaluated in a clinical trial conducted with the NHS to evaluate its ability to detect signs of cardiovascular disease.

Communication

Pharmaceutical Technology

JUNE 23, 2025

Eylea is approved in four indications in Europe: the treatment of ‘wet’ age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), visual impairment due to diabetic macular oedema (DME) and visual impairment due to myopic choroidal neovascularisation (myopic CNV).

Biosimilars

Pharmaceutical Technology

JULY 21, 2025

Fangzhou has signed a memorandum of understanding (MoU) with Novo Nordisk to collaborate on the management of serious chronic diseases including obesity and diabetes. GlobeNewswire.

Diabetes

Pharmaceutical Technology

JULY 31, 2025

Preclinical data with another of the company’s uncouplers, TLC-3595, showed that lowered blood sugar in mice by as much as 40%, on par with semaglutide, as per a poster at the American Diabetes Association 2024 meeting.

Packaging

Pharmaceutical Technology

JULY 4, 2025

This will largely be driven by the company’s glucagon like peptide-1 receptor agonist (GLP-1RA) tirzepatide, sold under the brand names Mounjaro and Zepbound for weight loss and type 2 diabetes respectively.

Biosimilars

pharmaphorum

JULY 1, 2025

Skip to main content Tuesday 1 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Vaccines

Pharmaceutical Technology

JUNE 12, 2025

The drugmaker’s flagship drug semaglutide, known under the brand names Wegovy and Ozempic for obesity and type 2 diabetes treatment respectively, targets the glucagon-like peptide-1 receptor (GLP-1R), a key component of the incretin system.

Diabetes

pharmaphorum

JUNE 6, 2025

Skip to main content Friday 6 June 2025 twitter linkedin facebook rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

pharmaphorum

JUNE 17, 2025

Skip to main content Tuesday 17 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

Pharmaceutical Technology

AUGUST 11, 2025

MV: We’ve seen manufacturers try to sell diabetes and obesity drugs to consumers through third-party online pharmacies. That’s an unintended consequence, which is unfortunately also possible. Can we glean trends from that?

Drug Pricing

Pharmaceutical Technology

JUNE 18, 2025

Find out more Fleischer said that the programme will provide more services for patients receiving its glucagon-like peptide 1 receptor agonist (GLP-1RA) semaglutide, which is marketed as Wegovy for weight loss and Ozempic in type 2 diabetes, including fitness and dietary advice.

Communication

pharmaphorum

JUNE 30, 2025

Skip to main content Monday 30 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

Pharmaceutical Technology

JULY 30, 2025

AstraZeneca did not respond to this news service for a comment, but in a July 5 letter to the board, an AstraZeneca spokesperson said that Farxiga accounts for only a fraction of the state’s spending—$20–30 million—while Maryland spends $6 billion on diabetes care.

Drug Pricing

Pharmaceutical Technology

AUGUST 7, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial (..)

Packaging

pharmaphorum

JULY 1, 2025

Skip to main content Tuesday 1 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

Pharmaceutical Technology

JULY 25, 2025

Reports LOA and PTSR Model - EBI-031 in Diabetic Macular Edema Data Insights The gold standard of business intelligence. Reports LOA and PTSR Model - EBI-031 in Diabetic Macular Edema Data Insights The gold standard of business intelligence. Find out more Sign up for our daily news round-up!

Insurance Coverage and Processing

Pharmaceutical Technology

AUGUST 6, 2025

Novo Nordisk has announced the filing of 14 new lawsuits against the sale of unapproved compounded drugs claiming to contain semaglutide, an active ingredient in its weight-loss and diabetes drugs, Wegovy and Ozempic, respectively.

Compounding

pharmaphorum

JULY 7, 2025

Skip to main content Monday 7 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Insurance Coverage and Processing

Pharmaceutical Technology

AUGUST 1, 2025

Eli Lilly is attempting to join fellow pharma companies with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) – drugs originally approved for treating diabetes – gaining expanded label expansions in cardiovascular indications.

Packaging

pharmaphorum

JUNE 27, 2025

Skip to main content Friday 27 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

pharmaphorum

JULY 1, 2025

Skip to main content Tuesday 1 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

Pharmaceutical Technology

AUGUST 7, 2025

Using real-world data to support vaccine outreach and education Buy Reports Newsletters PT News Mounjaro and Zepbound fuel strong Q2 growth for Eli Lilly Eli Lilly reported $15.56bn in revenue, driven by its weight loss and diabetes drugs, intensifying pressure on rival Novo Nordisk. Credit: bella1105 via Shutterstock.com.

Diabetes

pharmaphorum

JULY 2, 2025

Skip to main content Wednesday 2 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

Pharmaceutical Technology

AUGUST 11, 2025

Eli Lilly has announced that it will take up the option of a confidential discount in Germany for Mounjaro in Type 2 diabetes (T2D). Brendan Melck August 11, 2025 Share Copy Link Share on X Share on Linkedin Share on Facebook Price negotiations between the GKV-Spitzenverband and the company for Mounjaro in T2D have already been concluded.

Communication

pharmaphorum

JUNE 26, 2025

Skip to main content Thursday 26 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

Pharmaceutical Technology

AUGUST 6, 2025

Using real-world data to support vaccine outreach and education Buy Reports Newsletters PT News Novo Nordisk’s diabetes and weight loss drug sales growth decelerates H1 sales growth for Novo’s segment that includes Ozempic and Wegovy was down from the same period in 2024. KK Stock via Shutterstock.com.

Diabetes

pharmaphorum

JUNE 19, 2025

Skip to main content Thursday 19 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Vaccines

pharmaphorum

AUGUST 8, 2025

Skip to main content Friday 8 August 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

Pharmaceutical Technology

AUGUST 7, 2025

Skip to site menu Skip to page content Switch language: translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Sectors Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial (..)

Insurance Coverage and Processing

pharmaphorum

JULY 22, 2025

Skip to main content Tuesday 22 July 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes

pharmaphorum

AUGUST 7, 2025

Skip to main content Thursday 7 August 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views (..)

Diabetes